Literature DB >> 31532472

Treatment of Refractory Chronic Pruritus of Unknown Origin With Tofacitinib in Patients With Rheumatoid Arthritis.

Fang Wang1,2, Caroline Morris1, Nancy D Bodet1,2, Brian S Kim1,2,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31532472     DOI： 10.1001/jamadermatol.2019.2804

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  4 in total

1.  TRPV1 in Pain and Itch.

Authors:  Fengxian Li; Fang Wang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Evaluation of apremilast in chronic pruritus of unknown origin: A proof-of-concept, phase 2a, open-label, single-arm clinical trial.

Authors:  Marie Clark; Fang Wang; Nancy D Bodet; Brian S Kim
Journal:  Health Sci Rep       Date:  2020-04-23

Review 3.  Pruritus as a Distinctive Feature of Type 2 Inflammation.

Authors:  Simone Garcovich; Martina Maurelli; Paolo Gisondi; Ketty Peris; Gil Yosipovitch; Giampiero Girolomoni
Journal:  Vaccines (Basel)       Date:  2021-03-23

4.  Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies.

Authors:  Brian S Kim; Jonathan I Silverberg; Sonja Ständer; Gil Yosipovitch; Eric L Simpson; Marco DiBonaventura; Urs Kerkmann; Saleem A Farooqui; Pinaki Biswas; Hernan Valdez; Michael C Cameron
Journal:  Dermatitis       Date:  2021-10-01       Impact factor: 4.845
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.